Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 320,690 Shares of Stock

Posted by Teresa Graham on Mar 14th, 2025

Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc bought 320,690 shares of the stock in a transaction on Tuesday, March 11th. The stock was purchased at an average cost of $11.49 per share, with a total value of $3,684,728.10. Following the purchase, the director now directly owns 16,040,851 shares of the company’s stock, valued at approximately $184,309,377.99. This represents a 2.04 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

On Thursday, March 13th, Ecor1 Capital, Llc purchased 468,356 shares of Zymeworks stock. The stock was purchased at an average cost of $12.48 per share, with a total value of $5,845,082.88.
On Friday, January 17th, Ecor1 Capital, Llc acquired 19,748 shares of Zymeworks stock. The stock was purchased at an average price of $13.87 per share, with a total value of $273,904.76.
On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The stock was acquired at an average cost of $14.01 per share, with a total value of $546,796.29.
On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The stock was acquired at an average price of $13.39 per share, with a total value of $992,533.75.
On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were acquired at an average price of $13.13 per share, for a total transaction of $2,679,806.74.
On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The shares were acquired at an average cost of $14.07 per share, with a total value of $295,765.47.
On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The stock was bought at an average cost of $14.78 per share, for a total transaction of $2,333,466.40.
On Monday, December 30th, Ecor1 Capital, Llc purchased 58,988 shares of Zymeworks stock. The stock was bought at an average price of $14.47 per share, with a total value of $853,556.36.
On Tuesday, December 24th, Ecor1 Capital, Llc acquired 11,958 shares of Zymeworks stock. The shares were bought at an average price of $14.12 per share, for a total transaction of $168,846.96.
On Thursday, December 26th, Ecor1 Capital, Llc bought 16,692 shares of Zymeworks stock. The stock was bought at an average cost of $14.38 per share, with a total value of $240,030.96.

Zymeworks Stock Up 2.2 %

NYSE:ZYME opened at $12.55 on Friday. Zymeworks Inc. has a twelve month low of $7.97 and a twelve month high of $17.70. The firm has a market capitalization of $873.19 million, a price-to-earnings ratio of -8.37 and a beta of 1.13. The stock’s 50 day moving average price is $13.96 and its two-hundred day moving average price is $13.65.

Analyst Ratings Changes

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target on the stock in a report on Monday, December 16th. Citigroup boosted their target price on Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, March 7th. Lifesci Capital initiated coverage on shares of Zymeworks in a research note on Tuesday. They set an “outperform” rating and a $30.00 price target for the company. HC Wainwright lifted their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Monday. Finally, Wells Fargo & Company increased their target price on shares of Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.00.

Get Our Latest Stock Report on ZYME

Hedge Funds Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently made changes to their positions in ZYME. Blackstone Inc. lifted its stake in Zymeworks by 2,171.4% in the fourth quarter. Blackstone Inc. now owns 569,715 shares of the company’s stock valued at $8,341,000 after acquiring an additional 544,633 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Zymeworks in the 4th quarter valued at about $6,629,000. Schroder Investment Management Group acquired a new stake in Zymeworks in the 4th quarter valued at about $4,892,000. Assenagon Asset Management S.A. grew its holdings in Zymeworks by 93.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company’s stock worth $9,403,000 after purchasing an additional 311,107 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in Zymeworks by 565.8% during the fourth quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company’s stock worth $4,833,000 after purchasing an additional 280,544 shares during the period. 92.89% of the stock is owned by institutional investors.

About Zymeworks

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.